Pemetrexed in small-cell lung cancer: background and review of the ongoing GALES pivotal trial

References

• Kamangar F, Dores M, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J. Clin. Oncol.24(14), 2137–2215 (2006).
   PubMed Web of Science ®Google Scholar
• Govindan R, Page N, Morgensztern D et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the Surveillance, Epidemiologic, and End Results database. J. Clin. Oncol.24(28), 4539–4544 (2006).
   PubMed Web of Science ®Google Scholar
• Socinski MA, Weissman C, Hart LL et al. Randomized Phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer. J. Clin. Oncol.24(30), 4840–4847 (2006).
   PubMed Web of Science ®Google Scholar
• Hanauske AR, Chen V, Paoletti P, Niyikiza C. Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist6(4), 363–373 (2001).
   PubMed Web of Science ®Google Scholar
• Schutlz RM, Patel VF, Worzalla JF, Shih C. Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514. Anticancer Res.19, 437–443 (1999).
   PubMed Web of Science ®Google Scholar
• Shih C, Thornton DE. Preclinical pharmacology studies and the clinical development of a novel multitargeted antifolate, MTA (LY231514). In: Antifolate Drugs in Cancer Jackman AL (Ed.). Humana Press, Totowa, NJ, USA 183–201 (1999).
   Google Scholar
• Britten CD, Izbicka E, Hilsenbeck S et al. Activity of the multitargeted antifolate LY231514 in the human tumor cloning assay. Cancer Chemother. Pharmacol.44, 105–110 (1999).
   PubMed Web of Science ®Google Scholar
• Teicher BA, Chen V, Shih C et al. Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts. Clin. Cancer Res.6, 1016–1023 (2000).
   PubMed Web of Science ®Google Scholar
• Niyikiza C, Baker SD, Seitz ED et al. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol. Cancer Ther.1(7), 545–552 (2002).
   PubMed Web of Science ®Google Scholar
• Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol.21(14), 2636–2644 (2003).
   PubMed Web of Science ®Google Scholar
• Hanna N, Shepherd FA, Fossella FV et al. Randomized Phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol.22, 1589–1597 (2004).
   PubMed Web of Science ®Google Scholar
• Demarinis F, Paul S, Hanna N, Chang Yao Tsao T, Lim HL, Adachi S. Survival update for the Phase III study of pemetrexed vs docetaxel in non-small cell lung cancer (NSCLC). Presented at: Proceedings of the 42nd Annual Meeting of the American Society of Clinical Oncology June 2–6, Atlanta, GA, USA (2006) (Abstract 7133).
   Google Scholar
• Chute JP, Chen T, Feigal E, Simon R, Johnson BE. Twenty years of Phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J. Clin. Oncol.17(6), 1794–1801 (1999).
   PubMed Web of Science ®Google Scholar
• Pujol JL, Carestia L, Daures J. Is there a case for cisplatin in the treatment of small cell lung cancer? A meta analysis of randomised trials of a cisplatin-containing regimen versus a regimen without this alkalylating agent. Br. J. Cancer83(1), 8–15 (2000).
   PubMed Web of Science ®Google Scholar
• Mascaux C, Paesmans M, Berghmans T et al. A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer30(1), 23–36 (2000).
   PubMed Web of Science ®Google Scholar
• Bunn PA Jr. Review of therapeutic trials of carboplatin in lung cancer. Semin. Oncol.16(2 Suppl. 5), 27–33 (1989).
   PubMedGoogle Scholar
• Gatzemeier U, Hossfeld DK, Neuhauss R, Reck M, Achterrath W, Lenaz L. Phase II and III studies with carboplatin in small cell lung cancer. Semin. Oncol.19(1 Suppl. 2), 28–36 (1992).
   PubMedGoogle Scholar
• Thatcher N, Lind M. Carboplatin in small cell lung cancer. Semin. Oncol.17(1 Suppl. 2), 40–48 (1990).
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Ettinger DS. Carboplatin in the treatment of small cell lung cancer. Oncologist3(3), 143–154 (1998).
   PubMedGoogle Scholar
• Kosmidis PA, Samantas E, Fountzilas G et al. Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: a randomized Phase III study. Hellenic Cooperative Oncology Group for Lung Cancer Trials. Semin. Oncol.21(3 Suppl. 6), 23–30 (1994).
   PubMedGoogle Scholar
• Lassen U, Kristjansen PE, Osterlind K et al. Superiority of cisplatin or carboplatin in combination with teniposide and vincristine in the induction chemotherapy of small-cell lung cancer. A randomized trial with 5 years follow up. Ann. Oncol.7, 365–371 (1996).
   PubMed Web of Science ®Google Scholar
• Hanna N, Ansari R, Bhatia S et al. Pemetrexed in patients with relapsed small cell lung cancer (SCLC). A Phase II study of the Hoosier Oncology Group. J. Clin. Oncol.24(S18 Suppl. 1), 7063 (2006).
   Google Scholar
• Noda K, Nishiwaki Y, Kawahara M et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive stage small-cell lung cancer. New Engl. J. Med.346(2), 85–91 (2002).
   PubMed Web of Science ®Google Scholar
• Hanna N, Bunn PA, Langer C et al. Randomized Phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J. Clin. Oncol.24(13), 2038–2043 (2006).
   PubMed Web of Science ®Google Scholar
• Eckardt JR, von Pawel J, Papai Z et al. Open-label, multicenter, randomized, Phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer. J. Clin. Oncol.24(13), 2044–2051 (2006).
   PubMed Web of Science ®Google Scholar
• Reck M, von Pawel J, Macha HN et al. Efficient palliation in patients with small-cell lung cancer by a combination of paclitaxel, etoposide and carboplatin: quality of life and 6-years’-follow-up results from a randomised Phase III trial. Lung Cancer53(1), 67–75 (2006).
   PubMed Web of Science ®Google Scholar
• Mavroudis D, Papadakis E, Veslemes M et al. A multicenter randomized clinical trial comparing paclitaxel–cisplatin–etoposide versus cisplatin–etoposide as front-line treatment in patients with small cell lung cancer. Ann Oncol.12(4), 463–470 (2001).
   PubMed Web of Science ®Google Scholar
• Niell HB, Herndon JE II, Miller AA et al. Randomized Phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. J. Clin. Oncol.23(16), 3752–3759 (2005).
   PubMed Web of Science ®Google Scholar
• James LE, Rudd R, Gower NH et al. A Phase III randomised comparison of gemcitabine/carboplatin (GC) with cisplatin/etoposide (PE) in patients with poor prognosis small cell lung cancer (SCLC). Presented at: Proceedings of the 38th Annual Meeting of the American Society of Clinical Oncology. May 18–21, Orlando, FL, USA (2002) (Abstract 1170).
   Google Scholar
• Ohe Y, Negoro S, Matsui K et al. Phase I–II study of amrubicin and cisplatin in previously untreated patients with extensive stage small cell lung cancer. Ann. Oncol.16(3), 430–436 (2005).
   PubMed Web of Science ®Google Scholar
• Yana T, Negoro S, Takada M et al. Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study. Invest. New Drugs (2006) (Epub ahead of print).
   Google Scholar
• Pujol JL, Breton JL, Gervais R et al. A prospective randomized Phase III, double-blind, placebo-controlled study of thalidomide in extended-disease (ED) SCLC patients after response to chemotherapy (CT): an intergroup study FNCLCC Cleo04 - IFCT 00-01. Presented at: Proceedings of the 42nd Annual Meeting of the American Society of Clinical Oncology. June 2–6, Atlanta, GA, USA (2006) (Abstract 7057).
   Google Scholar